- Gilead Sciences (NASDAQ:GILD) announces that Norbert Bischofberger, PhD, will step down from his role as Executive VP, R&D and Chief Scientific Officer, effective at the end of April.
- John McHutchison, MD, currently Executive VP, Clinical Research, will be appointed as Chief Scientific Officer.
- Also, Andrew Cheng, MD, PhD, Executive VP, Clinical Research & Development Operations, will be appointed as Chief Medical Officer.
- Both will report to John Milligan, PhD, Gilead’s President and CEO.
- Dr. McHutchison joined Gilead in 2010. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute.
- Dr. Cheng joined Gilead in 1999 to lead company’s development-stage programs in HIV/AIDS. He was named Executive VP in 2015.